Context Therapeutics submits IND for CTIM-76 Phase 1 trial in CLDN6-positive cancers

Context Therapeutics Inc.

IND filed March 28, 2024 with FDA for CTIM-76, a CLDN6 x CD3 bispecific antibody.
Phase 1 dose escalation/expansion trial planned in CLDN6-positive gynecologic and testicular cancers.
CEO Martin Lehr calls IND submission a significant milestone for the company.
Company set aggressive 2021 timeline and prioritized CTIM-76 as potentially best-in-class therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.